Drug intelligence / Profile preview

PBP1603

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PBP1603 is a biosimilar monoclonal antibody candidate targeting complement component 5 (C5). Developed by Prestige Biopharma (PBK), it is designed as a biosimilar to eculizumab (Soliris). The drug works by binding to the C5 protein, thereby inhibiting its cleavage into C5a and C5b and preventing the formation of the terminal complement complex (C5b-9). This mechanism is intended to treat complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is currently in preclinical development.

Other names: eculizumab biosimilar

Targets

Beyond the preview

Go deeper on PBP1603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBP1603.

Explore the full profile